LYELL IMMUNOPHARMA INC (LYEL) Stock Income Statement
NASDAQ:LYEL - US55083R1041 - Common Stock
12.15 USD
+0.43 (+3.67%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 60.00K | 61.00K | 130.00K | 84.68M | 10.65M | |||
| Operating Expenses | 215.23M | 220.34M | 247.14M | 271.74M | 225.12M | |||
| Research and Development | 168.44M | 172.77M | 185.72M | 164.32M | 134.98M | |||
| Selling, General, and Administrative Expenses | 50.12M | 52.04M | 66.98M | 117.31M | 89.06M | |||
| Operating Income | -215.17M | -220.27M | -247.01M | -187.06M | -214.47M | |||
| Interest Income/Expense | 18.02M | 24.07M | 23.45M | 5.99M | 910.00K | |||
| Other Income/Expense | 5.68M | 4.69M | 1.85M | 2.95M | 100.00K | |||
| Non Recurring Items | -139.92M | -151.48M | -12.92M | -5.00M | -36.75M | |||
| Income Before Taxes | -331.40M | -342.99M | -234.63M | -183.12M | -250.22M | |||
| Net Income | -331.40M | -342.99M | -234.63M | -183.12M | -250.22M | |||
| EBITDA | -198.89M | -200.64M | -226.76M | -169.04M | -200.85M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -23.61 | -26.23 | -18.70 | -14.67 | -20.61 | |||
| Non GAAP EPS | -13.83 | -15.80 | -15.60 | -15.00 | N/A | |||
| Statistics | ||||||||
| Profit Margin | -552328.33% | -562285.25% | -180486.15% | -216.25% | -2349.48% | |||
| Operating Profit Margin | -358621.67% | -361104.92% | -190006.15% | -220.90% | -2013.80% | |||
All data in USD